High rates of flares after anti‐tumor necrosis factor withdrawal in pediatric inflammatory bowel disease: A multi‐center study
Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVES: Outcomes of anti-tumor necrosis factor (anti-TNF) discontinuation in pediatric patients with inflammatory bowel disease (IBD) remain unclear. We aimed to quantify relapse and biologic re-initiation rates following anti-TNF withdrawal in patients in sustained clinical remission for at least 6 months. METHODS: Patients' characteristics were recorded at the time of anti-TNF discontinuation, at the time of flare, or at the end of follow-up, with a minimum follow-up of 1 year. A flare was defined as clinical, biochemical, or endoscopic activity leading to hospitalization, systemic corticosteroids, and/or initiation of a biologic. RESULTS: This multicenter retrospective study from the Pediatric IBD Porto Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) included 83 children from 21 centers (46 [55%] males, 59 Crohn's disease [CD], 24 ulcerative colitis [UC]), who discontinued anti-TNF. At the time of anti-TNF withdrawal, the median age was 14.8 years (interquartile range 12.4-16.9); 93% had biochemical remission, and 68% of those undergoing endoscopy were in endoscopic remission. Within 12 and 24 months, 45/83 (54%) and 56/74 (76%) experienced a flare, and 29/83 (35%) and 47/68 (69%) re-initiated a biologic, respectively. Overall, flare and biologic re-initiation rates were similar in CD and UC, between those with biochemical or endoscopic remission, and among those maintained on immunomodulators (n = 33) or 5-aminosalicylates (n = 20). Univariate and multivariable Cox models did not identify baseline predictors of relapse or biologic re-initiation. CONCLUSIONS: Discontinuing anti-TNF therapy in pediatric IBD patients in clinical remission is associated with high rates of disease flare and treatment re-initiation. This provides quantitative data to help balance the benefits and risks when considering anti-TNF withdrawal.
DOI: 10.1002/jpn3.70680
Authors: Maya Granot, Anouk Camman, Saverio Pochesci, Lissy de Ridder, Salvatore Oliva, Patrizia Alvisi, Ben Kang, Ramit Magen Rimon, Kaija‐Leena Kolho, Benedicte Pigneur, Dror S. Shouval, Iva Hojsak, Paulina Krawiec, Caterina Strisciuglio, Laura Gianolio, Jarosław Kierkuś, Helena J. Rolandsdotter, Firas Rinawi, Anat Yerushalmy‐Feler, Marta Velasco Rodríguez‐Belvís, Assaf Hoofien, Karl Mårild, Batia Weiss, Richard K. Russell, Yael Haberman
Institutions: Tel Aviv University, Sheba Medical Center, Edmond and Lily Safra Children's Hospital, Erasmus MC, Erasmus MC - Sophia Children’s Hospital, Leiden University Medical Center, Willem-Alexander Kinderziekenhuis, Policlinico Umberto I, Sapienza University of Rome, Ospedale Maggiore Carlo Alberto Pizzardi, Kyungpook National University, Technion – Israel Institute of Technology, Rambam Health Care Campus, University of Helsinki, Helsinki University Hospital, Helsinki Children's Hospital, Hôpital Necker-Enfants Malades, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Schneider Children's Medical Center, University of Zagreb, Children's Hospital Zagreb, Medical University of Lublin, University of Campania "Luigi Vanvitelli", University of Milan, Ospedale dei Bambini Vittore Buzzi, Children's Memorial Health Institute, Karolinska Institutet, Stockholm South General Hospital, Sachs' Children and Youth Hospital, Emek Medical Center, Tel Aviv Sourasky Medical Center, Hospital Infantil Universitario Niño Jesús, Kaplan Medical Center, Cincinnati Children's Hospital Medical Center, University of Cincinnati
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,780
OpenAlex ID: W7234925169
